These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
212 related articles for article (PubMed ID: 12547)
41. [Metals in the metabolism of cerebral neurotransmitters. Physiological importance and metal-enzyme topographic relationships]. De Falco FA; Campanella G Acta Neurol (Napoli); 1975; 30(2):121-68. PubMed ID: 240251 [No Abstract] [Full Text] [Related]
42. Monoamines in the human neostriatum: topographic distribution in normals and in Parkinson's disease and their role in akinesia, rigidity, chorea, and tremor. Fahn S; Libsch LR; Cutler RW J Neurol Sci; 1971 Dec; 14(4):427-55. PubMed ID: 5125758 [No Abstract] [Full Text] [Related]
43. Neurotransmitters in the human and nonhuman primate basal ganglia. Haber SN Hum Neurobiol; 1986; 5(3):159-68. PubMed ID: 2876974 [TBL] [Abstract][Full Text] [Related]
44. Serotonin modulation of the basal ganglia circuitry: therapeutic implication for Parkinson's disease and other motor disorders. Di Matteo V; Pierucci M; Esposito E; Crescimanno G; Benigno A; Di Giovanni G Prog Brain Res; 2008; 172():423-63. PubMed ID: 18772045 [TBL] [Abstract][Full Text] [Related]
45. Biochemical mechanisms and management of choreiform movement disorders. de Silva L Drugs; 1977 Oct; 14(4):300-10. PubMed ID: 144049 [No Abstract] [Full Text] [Related]
46. Beta-adrenergic receptor subtypes in the basal ganglia of patients with Huntington's chorea and Parkinson's disease. Waeber C; Rigo M; Chinaglia G; Probst A; Palacios JM Synapse; 1991 Aug; 8(4):270-80. PubMed ID: 1656540 [TBL] [Abstract][Full Text] [Related]
47. Potential nondopaminergic drugs for Parkinson's disease. Silverdale MA; Fox SH; Crossman AR; Brotchie JM Adv Neurol; 2003; 91():273-91. PubMed ID: 12442686 [No Abstract] [Full Text] [Related]
48. Role of dopamine in the nervous system. Barbeau A Monogr Hum Genet; 1972; 6():114-36. PubMed ID: 4577118 [No Abstract] [Full Text] [Related]
49. Progressive supranuclear palsy: postmortem chemical analysis. Young AB Ann Neurol; 1985 Nov; 18(5):521-2. PubMed ID: 2866753 [No Abstract] [Full Text] [Related]
51. Some aspects of dopamine in the basal ganglia. Carlsson A Res Publ Assoc Res Nerv Ment Dis; 1976; 55():181-9. PubMed ID: 12545 [No Abstract] [Full Text] [Related]
52. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. Bernheimer H; Birkmayer W; Hornykiewicz O; Jellinger K; Seitelberger F J Neurol Sci; 1973 Dec; 20(4):415-55. PubMed ID: 4272516 [No Abstract] [Full Text] [Related]
53. Insight Into the Emerging Role of Striatal Neurotransmitters in the Pathophysiology of Parkinson's Disease and Huntington's Disease: A Review. Jamwal S; Kumar P Curr Neuropharmacol; 2019; 17(2):165-175. PubMed ID: 29512464 [TBL] [Abstract][Full Text] [Related]
54. [Relationship between brain neuroregulators and hypothalamic hormones]. Zile RK; Klusha VE Probl Endokrinol (Mosk); 1979; 25(6):73-9. PubMed ID: 42901 [No Abstract] [Full Text] [Related]
55. 5-hydroxyindoleacetic and homovanillic acid levels in the cerebrospinal fluid of healthy volunteers and patients with Parkinson's syndrome. Johansson B; Roos BE Life Sci; 1967 Jul; 6(13):1449-54. PubMed ID: 6035772 [No Abstract] [Full Text] [Related]
59. Neuronal control of neurochemical processes in the basal ganglia. Heller A; Hoffmann PC UCLA Forum Med Sci; 1975; (18):205-17. PubMed ID: 173060 [No Abstract] [Full Text] [Related]
60. Neurotransmitter receptor alterations in Parkinson's disease. Reisine TD; Fields JZ; Yamamura HI Life Sci; 1977 Aug; 21(3):335-43. PubMed ID: 197361 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]